RxDoctor Payments Data

Rakesh Sahni, MD

Cardiovascular Disease · Clark, NJNPI 1265636526

Payments from drug & device makers

$14,379in general payments, 2019–2025

Across 591 payments — averaging $24.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Irhythm Technologies, Inc.$984
  • Boston Scientific$960
  • Novartis$862
  • Novo Nordisk$756
  • Masimo Corporation$709
  • plus $7K from 46 others

What the payments were for

  • Speaking & faculty fees$290%
  • Travel & lodging$3,55125%
  • Food & beverage$10,71575%
  • Education$851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,379 in reported general payments places this provider in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$554,668
Medicare patients
852
Services billed
3,709

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan201$253,170
EliquisApixaban174$188,267
FarxigaDapagliflozin Propanediol94$110,026
XareltoRivaroxaban88$86,023
Repatha SureclickEvolocumab71$81,761
JardianceEmpagliflozin30$32,354
Ranolazine ErRanolazine245$26,161
OzempicSemaglutide21$24,846
VerquvoVericiguat11$15,569
Praluent PenAlirocumab15$12,595
JanuviaSitagliptin Phosphate14$12,100
BrilintaTicagrelor14$12,097
Atorvastatin Calcium575$7,130
Metoprolol Succinate348$4,502
Rosuvastatin Calcium190$3,771

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$862$253,170201 claims
PfizerEliquis$357$188,267174 claims
AstraZenecaFarxiga, Brilinta$700$122,123108 claims
Johnson & JohnsonXarelto$191$86,02388 claims
Boehringer IngelheimJardiance$155$32,35430 claims
MerckVerquvo, Januvia$458$27,67025 claims
Novo NordiskOzempic$756$24,84621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Clark

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →